Eversana, a global life-sciences commercial services firm, is partnering with the Institute for Clinical and Economic Review (ICER) to promote use of transparent, robust, repeatable indirect comparisons in health technology assessments.
ICER produces drug assessments and other reviews covering the comparative clinical effectiveness, as well as cost effectiveness, of health-care interventions. ICER reportedly will use Eversana’s technology platform to conduct indirect treatment comparisons to cull comparative effectiveness data, outside of head-to-head clinical trials. The organization started testing the platform earlier this year.
According to ICER’s Director of Evidence Synthesis, Foluso Agboola, “Eversana’s platform will make us more efficient in how we conduct high-quality and reproducible indirect treatment comparisons. They’ve built a best-in-class technology that will help us advance many ongoing initiatives across the U.S. and further support our mission.”
Eversana’s web-based platform combines advanced indirect comparison methods with computing technology to indirectly compare treatments that have not been compared directly in clinical trials. The technology reportedly can incorporate both clinical trial and real-world data, with transparent methods scientifically validated by global experts and benchmarked against standards set by health technology assessment agencies, payers and regulatory bodies.